Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG-350A plus pembrolizumab in advanced epithelial tumors
NCT05165433Phase 1Completed
- Sponsor
- Akamis Bio
- Start
- Apr 2022
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of NG-350A in Epithelial tumor and metastatic cancer, sponsored by Akamis Bio. Primary endpoint: Adverse Events. Started Apr 2022; status: completed.
02
Drugs
NG-350A
03
Conditions
Epithelial tumormetastatic cancer
Beyond the preview
Go deeper on NCT05165433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165433.